Doxorubicin Docetaxel

Docetaxel + capecitabine Docetaxel 75 mg/m2 IV over 1 hour, day 1 Capecitabine 2000-2500 mg/m2 per day orally divided twice daily for 14 days Repeat cycles every 21 days Epirubicin + docetaxel" Epirubicin 70-90 mg/m2 IV bolus Followed by Docetaxel 70-90 mg/m2 IV over 1 hour Repeat cycles every 21 daysv Doxorubicin + docetaxel" Doxorubicin 50 mg/m2 IV bolus, day 1 Followed by Docetaxel 75 mg/m2 IV over 1 hour, day 1 Repeat cycles every 21 days"... 

DOCETAXEL DOXORUBICIN t plasma concentrations of docetaxel (t AUC by 50-70%) with t efficacy and also t risk of toxicity, particularly when docetaxel is administered after doxorubicin, compared with administration of docetaxel alone Uncertain possibly due to interference with hepatic microsomal enzymes Monitor closely for T incidence of bone marrow suppression, neurotoxicity, myalgia and fatigue... 

AZATHIOPRINE CHLORAMBUCIL, CISPLATIN, CYCLOPHOSPHAMIDE, CYTARABINE, DACTINOMYCIN (ACTINO-MYCIN D), DAUNORU-BICIN, DOCETAXEL, DOXORUBICIN, ETOPO-SIDE, FLUOROURACIL, MELPHALAN, MERCAPTO-PURINE, MITOXANTRONE, VINCA ALKALOIDS t risk of myelosuppression and immunosuppression. Deaths have occurred following profound myelosuppression and severe sepsis Additive myelotoxic effects. Azathioprine is metabolized to 6-mercatopurine in vivo, which results in additive myelosuppression, immunosuppression and hepatotoxicity Avoid co-administration... 

Actinomycin D, bisantrene, chlorambncil, cisplatin, cytarabine, dannornbicin, docetaxel, doxorubicin, epirn-bicin, etoposide, flnoro uracil, hydroxyurea, mitomycin C, mitoxantrone, paclitaxel, tamoxifen, topotecan, taxol, vinblastine, vincristine. 

Clinically important, potentially hazardous interactions with altretamine, amikacin, aminoglycosides, antineoplastics, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, corticosteroids, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, estramustine, etoposide, fludarabine, fluorouracil, gemcitabine, gentamicin, hydroxyurea, idarubicin, ifosfamide, indomethacin, kanamycin, levamisole, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, neomycin, pentostatin, plicamycin, procarbazine, streptomycin, streptozocin, thioguanine, thiotepa, tobramycin, tretinoin, uracil, vinblastine, vincristine, vinorelbine... 

AC, doxorubicin, cyclophosphamide BCIRG, Breast Cancer International Research Croup CALCB, Cancer and Leukemia Croup B FAC, fluorouracil, doxorubicin, cyclophosphamide NSABP, National Surgical Adjuvant Breast and Bowel Project Pac, paclitaxel TAC, docetaxel, doxorubicin, cyclophosphamide. 

Chemotherapeutic agents that have significant cancer response when combined with hyperthermia (up to 43°C) include doxorubicin, melphalan, mitomycin C (MMC), mitoxantrone, gemcitabine, etoposide, and especially the platinum-based agents carboplatin and oxaliplatin (Mohamed et al., 2003 Sugarbaker et al., 2005). Agents that do not work well with hyperthermia include irinotecan, paclitaxel, docetaxel, 5-fluorouracil, and floxuridine (Mohamed et al., 2003 Sugarbaker et al., 2005). 

Syrigos KN, Michalaki B, Alevyzaki F, et al. A phase II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 2002 22 3583. 

Anticancer drugs Paclitaxel Docetaxel Vinblastine Vincristine Tipifarnib Diflomotecan Iiinotecan Doxorubicin Daunorubicin Etoposide Tenoposide Tamoxifen (i)... 

Investigators found that human breast cancer cell lines with BRCAl mutations showed a twofold to fourfold increase in apoptosis after treatment with ionizing radiation, cisplatin, or doxorubicin, compared with cells free of mutations. They also found that BRCAl tumor cell lines were resistant to other agents, such as paclitaxel (Taxol) and docetaxel (Taxotere), treatments used commonly in ovarian cancer and advanced-stage breast cancers. 

Acyclovir Erythromycin Ivermectin Itraconazole Rifampin Actinomycin D Daunorubicin Doxorubicin Docetaxel Epirubicin Etoposide Imatinib Irinotecan Paclitaxel Vinblastine Vincristine Amprenavir Indinavir Nelfinavir Ritonavir Saquinavir Cyclosporine A Tacrolimus Digoxin Quinidine Verapamil Diltiazem Aldosterone Cortisol Corticosterone Dexamethasone Hydrocortisone Cyclosporine Metkephamid Enkephalin... 

Paridaens, R., Van Aaelst, E, and Georgoulias, V. (2003), A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first line chemotherapy for metastatic breast cancer, Ann. Oncol., 14,433 440. 

Mrozek, E., Rhoades, C. A., Allen, J., Hade,E. M., and Shapiro, C. L. (2005), Phase I trial of liposomal encapsulated doxorubicin (Myocet D-99) and weekly docetaxel in advanced breast cancer patients, Ann. Oncol., 16,1087-1093. 

Black cohosh 2. Caffeine 3. Evening primrose oil 4. Scutellaria baicalensis 5. Starflower (borage) 1. Docetaxel 2. Paditaxel 3. Doxorubicin 4. Tamoxifen 5. Cisplatin 6. Vinorelbine t cytotoxic properties Unknown mechanism (black cohosh). Caffeine t cytotoxic effects of cisplatin wogonin present in Scutellaria enhances etoposide-induced apoptosis. Gamolenic acid found in evening primrose oil and borage potentiated the in vitro toxicity of paditaxel and vinorelbine, attributed to an unsaturated fatty acid as modulators of tumour cell chemosensitivity Be aware and avoid concomitant use... 

Breast CMF cyclophosphamide + methotrexate + 5-fluorouracil AC doxorubicin (Adriamycin) + cyclophosphamide Docetaxel ... 

An interaction of doxorubicin with the anti-HER2 receptor humanized monoclonal antibody, trastuzumab (Herceptin), has been reported. Most patients who received trastuzumab in early trials had been pretreated with anthracyclines. Despite this, preliminary information suggested that reduced systolic cardiac function was an adverse effect of trastuzumab (119). More recently, this problem has been further highlighted in a study of women with metastatic breast cancer (120). Patients who had not received prior anthracycline-containing adjuvant chemotherapy were at greater risk of cardiotoxicity when they received trastuzumab in combination with doxorubicin or cyclophosphamide (27 and 75% respectively), compared with only 11% of patients who received trastuzumab in combination with pachtaxel (120,121). The risk of cardiac events in patients treated with doxorubicin, cyclophosphamide, and trastuzumab increased markedly after a cumulative doxorubicin dose of 360 mg/m. This suggests synergistic cardiotoxicity with trastuzumab and doxorubicin. Trastuzumab is therefore currently licensed only for use in conjunction with pacli-taxel or docetaxel and not with conventional doxorubicin. 

Cardoso F, Ferreira FUho AF, Crown J, Dolci S, Paesmans M, Riva A, Di Leo A, Piccart MJ. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer results of a feasibihty study. Anticancer Res 2001 21(lB) 789-95. 

---